<aside> 💡
Founded in 2022 and headquartered in Tokyo, FerroptoCure Inc. is dedicated to providing new therapeutic options for patients with refractory cancers by targeting ferroptosis—a natural form of iron-dependent cell death triggered by the accumulation of lipid peroxidation. While cancer cells suppress this autonomous "self-destruct switch" using sophisticated antioxidant shields to survive high oxidative stress, FerroptoCure aims to dismantle these defenses to force tumors into self-destruction.
Under the leadership of CEO Yuji Otsuki, a former surgeon, the company focuses on a "synthetic lethality" strategy that simultaneously inhibits xCT (a transporter that imports cystine [an amino acid precursor for the powerful antioxidant glutathione]) and ALDH (an enzyme that detoxifies harmful aldehydes). This unique dual-targeting strategy offers a breakthrough for "refractory cancers" where conventional therapies have reached a standstill.
By attacking from a completely different angle—ferroptosis—and breaking down double defenses simultaneously, the company aims to dramatically increase the probability of successful treatment even in resistant tumors. The high acclaim received through various domestic and international awards highlights the company's technical excellence and vast market potential. Further breakthroughs and success from FerroptoCure are highly anticipated. （AS）
</aside>
FerroptoCure | Ferroptosisで病気を治す
Yuji Otsuki: Transforming Cancer Treatment with Ferroptosis-Based Therapies - The Healthcare Focus
Yuji Otsuki: Revolutionizing Oncology with Next-Generation Anticancer Drugs